Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatitis C treatment uptake among people who inject drugs in the oral direct‐acting antiviral era
Oluwaseun Falade‐Nwulia, Rachel E. Gicquelais, Jacquie Astemborski, et al.
Liver International (2020) Vol. 40, Iss. 10, pp. 2407-2416
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington
Maria A. Corcorran, Judith I. Tsui, John D. Scott, et al.
Drug and Alcohol Dependence (2021) Vol. 220, pp. 108525-108525
Open Access | Times Cited: 39
Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations
Meghan D. Morris, Claire McDonell, Annie Luetkemeyer, et al.
JAMA Network Open (2023) Vol. 6, Iss. 10, pp. e2338792-e2338792
Open Access | Times Cited: 14
Barriers to and impacts of hepatitis C treatment among people who inject drugs in Kenya: A qualitative study
Hannah N. Manley, Lindsey Riback, Mercy Nyakowa, et al.
PLOS Global Public Health (2025) Vol. 5, Iss. 1, pp. e0003284-e0003284
Open Access
How the rural risk environment underpins hepatitis C risk: Qualitative findings from rural southern Illinois, United States
Suzan M. Walters, David Frank, Marisa Felsher, et al.
International Journal of Drug Policy (2023) Vol. 112, pp. 103930-103930
Open Access | Times Cited: 12
HCV Microelimination for High-risk Special Populations
Chung‐Feng Huang, Guan‐Jhou Chen, Chien‐Ching Hung, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_3, pp. S168-S179
Closed Access | Times Cited: 12
Hepatitis C Treatment in Kentucky Medicaid Recipients with Concurrent Opioid Use Disorder: A Cross-Sectional Study
Olivia K. Sugarman, Brendan Saloner, Samantha J. Harris, et al.
Journal of General Internal Medicine (2025)
Closed Access
Facilitating access to direct-acting antivirals in a community-based point-of-diagnosis model for hepatitis C treatment: The role of the pharmacy team in the no one waits (NOW) study
Colleen A McGourty, Diana Ung, Mackenzie Clark, et al.
International Journal of Drug Policy (2025) Vol. 139, pp. 104768-104768
Open Access
A randomized controlled trial for a peer-facilitated telemedicine hepatitis c treatment intervention for people who use drugs in rural communities: study protocol for the “peer tele-HCV” study
Megan C. Herink, Andrew Seaman, Gillian Leichtling, et al.
Addiction Science & Clinical Practice (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 9
“Treated like a Human Being”: perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City
Shashi N. Kapadia, Yesenia Aponte-Meléndez, Alicia Rodrı́guez, et al.
Harm Reduction Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 9
Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial
Kristian Braathen Malme, Kathrine Stene‐Johansen, Ingvild Klundby, et al.
Viruses (2024) Vol. 16, Iss. 6, pp. 858-858
Open Access | Times Cited: 3
Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study
Kristian Braathen Malme, Kjersti Ulstein, Ane‐Kristine Finbråten, et al.
International Journal of Drug Policy (2023) Vol. 116, pp. 104044-104044
Open Access | Times Cited: 6
HCV treatment initiation in the era of universal direct acting antiviral coverage – Improvements in access and persistent barriers
Nathalie Jiang, Julie Bruneau, Iuliia Makarenko, et al.
International Journal of Drug Policy (2023) Vol. 113, pp. 103954-103954
Open Access | Times Cited: 5
Association between claims‐based setting of diagnosis and treatment initiation among Medicare patients with hepatitis C
Hao Zhang, Yuhua Bao, Kayla Hutchings, et al.
Health Services Research (2024) Vol. 59, Iss. 4
Open Access | Times Cited: 1
Peer-Assisted Telemedicine for Hepatitis C (PATHS): Process evaluation results from a State Opioid Response-funded program
Hunter Spencer, Gillian Leichtling, Jane Babiarz, et al.
Journal of Substance Use and Addiction Treatment (2024) Vol. 167, pp. 209510-209510
Closed Access | Times Cited: 1
Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C
Nicolas Nagot, Morgana D’Ottavi, Catherine Quillet, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 7
Hepatitis C treatment at a Swedish needle exchange program, a successful model of care – the ACTIONNE study
Marianne Alanko Blomé, Martin Bråbäck, Sara Alsterberg, et al.
International Journal of Drug Policy (2021) Vol. 96, pp. 103407-103407
Closed Access | Times Cited: 9
HCV communication within ego-centric networks of men and women who inject drugs
Marisa Felsher, Karin E. Tobin, Mark Sulkowski, et al.
Drug and Alcohol Dependence (2021) Vol. 229, pp. 109157-109157
Open Access | Times Cited: 6
Hepatitis C virus micro‐elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide
Chi‐Ming Tai, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences (2023) Vol. 40, Iss. 2, pp. 112-118
Open Access | Times Cited: 2
Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination
Kathleen Bryce, Colette Smith, Alison Rodger, et al.
Journal of Viral Hepatitis (2022) Vol. 30, Iss. 1, pp. 46-55
Open Access | Times Cited: 4
How to better improve the treatment and outcomes of HCV in psychiatric patients: review of a Belgian monocentric psychiatric center
S Chabert, Xavier Saloppé, B Delaunoit, et al.
Acta Gastro Enterologica Belgica (2024) Vol. 87, Iss. 2, pp. 223-228
Closed Access
Hepatitis C Virus Infection in People Who Inject Drugs
Jacqueline E. Sherbuk
Springer eBooks (2024), pp. 73-89
Closed Access
A road map to Hepatitis C Elimination: Yesterday, Today, and Tomorrow
Luis A Gonzalez Corro, Gregory M. Lucas, Kathleen R. Page
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 11
Open Access
Effect of Self-efficacy Among PWID treated with Direct-Acting Antivirals on HCV Treatment Initiation, Duration, Completion, Adherence, and Cure
Snehal Lopes, Irene Pericot‐Valverde, James Edward Dotherow, et al.
Drug and Alcohol Dependence (2024) Vol. 262, pp. 111384-111384
Closed Access
A comparison of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for the treatment of hepatitis C infection among people who inject drugs
Shana Yi, David Truong, Brian Conway
Journal of Virus Eradication (2024) Vol. 10, Iss. 3, pp. 100388-100388
Open Access
Identifying barriers and facilitators along the hepatitis C care cascade to inform human-centered design of contextualized treatment protocols for vulnerable populations in Austin, Texas: a qualitative study
Anmol Desai, Lauren O’Neal, Kia Reinis, et al.
Implementation Science Communications (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top